Gastric cancer usually is diagnosed in advanced stages and thus current medical practice
affords limited therapeutic options. However, recent studies established the role of human …

In patients with metastatic gastric cancer, median overall survival remains under 1 year and
standard chemotherapy regimens are not able to substantially improve the prognosis of the …

Although combination chemotherapy has been shown to be more effective than single
agents in advanced esophagogastric cancer, the better response rates have not fulfilled …

Despite some advances in the past few years, the search for effective treatment modalities
for advanced gastric and gastro-esophageal junction cancer is far from over. Available data …

Gastric and esophago-gastric junction (EGJ) adenocarcinoma are leading causes of cancer
mortality and morbidity worldwide. In this short update article, we outline novel key …

Introduction HER2 over-expression and/or amplification are present in 9-38% of gastric or
gastroesophageal junction (GEJ) cancers and are correlated to poor outcome. We …

Purpose The use of trastuzumab, a monoclonal antibody targeting the HER2 protein, in
combination with 5-fluorouracil/platinum-based chemotherapy improves survival in patients …

MSI high gastric cancer has a better prognosis and may not require adjuvant chemotherapy.
Trastuzumab, added to preoperative chemoradiotherapy in HER2-positive esophageal …

Background Gastric cancer is the fourth most common cancer worldwide. Surgery in
combination with multimodal therapy provides the only curative therapy until now. The …

Gastric cancer is heterogeneous in morphology, biology, genomics, and treatment response.
Alterations in human epidermal growth factor receptor 2 (HER2) overexpression …